[stock_market_widget type=”card” template=”basic2″ assets=”MAIA” realtime=”true” api=”yahoo-finance”]
Every cell in the human body carries a built-in limit on how many times it can divide. At the tips of each chromosome sits a stretch of repeating DNA called a telomere, and every time a cell copies itself, that stretch grows a little shorter. Eventually the telomere becomes too short to protect the chromosome, and the cell stops dividing or dies off. Scientists call this boundary the Hayflick limit, and it is one reason normal tissue does not grow without end. Cancer cells find a way around this rule. Most of them switch on an enzyme called telomerase, which rebuilds the telomere after each division and lets the cell keep multiplying indefinitely.
A newer class of cancer drugs tries to exploit that same trick against the tumor itself. Rather than simply blocking telomerase the way earlier compounds attempted, some of these molecules get absorbed directly into a cancer cell’s telomeres, where they interfere with the structure and eventually cause the chromosome tips to fail. Because healthy cells with low telomerase activity are far less affected, the approach is designed to hit tumors while sparing much of the surrounding tissue. Researchers also believe that when a telomere targeting agent is paired with a checkpoint inhibitor, a drug that helps the immune system recognize and attack cancer, the damage done to a tumor’s chromosomes can make it more visible to immune cells that were previously held back.
This approach is still new, and only a handful of companies are testing it in human trials. One of the companies furthest along is MAIA Biotechnology, Inc. (NYSE American: MAIA), a Chicago based, clinical stage biopharmaceutical company whose lead drug, ateganosine, is a telomere targeting therapy aimed at one of the hardest cancers to treat, advanced non small cell lung cancer that has already resisted standard treatment. In patients who have gone through multiple prior lines of therapy without success, doctors have historically had few options left, and outcomes tend to be poor.
MAIA has announced that enrollment in its pivotal Phase 3 trial, known as THIO-104, has reached 65 patients across 38 activated sites in six countries, including Taiwan, Romania, Turkey, Georgia, Poland and Hungary. The company said it expects to surpass 100 randomized patients by the end of 2026. THIO-104 is testing ateganosine, given ahead of a checkpoint inhibitor, against a doctor’s choice of standard chemotherapy in patients whose lung cancer has already progressed despite two prior treatment regimens. The trial’s main goal is to measure whether patients live longer on ateganosine than they would on standard third line chemotherapy.
Earlier results give some sense of why the company is moving forward with this design. In the Phase 2 study that preceded THIO-104, ateganosine combined with a checkpoint inhibitor produced a disease control rate of 90.5%, meaning that in the vast majority of patients the tumor either shrank or stopped growing for a period of time. Standard third line chemotherapy, by comparison, has historically produced disease control rates of only 25% to 35% in this same setting. The U.S. Food and Drug Administration granted ateganosine Fast Track designation in July 2025, a status meant to speed the review of therapies addressing a serious condition with limited existing treatment options.
Whether ateganosine can repeat that early promise in a larger, randomized trial is still an open question, and Phase 3 studies frequently produce results that look different from the smaller trials that came before them. What is clear is that MAIA has moved from a laboratory concept to patients being treated across multiple countries, and the company now has a defined timeline, more than 100 patients by year end, against which its progress can be measured. For a disease that still claims hundreds of thousands of lives each year, even incremental gains in third line treatment carry real weight for the patients who have already run out of other options.
